Mauna Kea Technologies announced a significant milestone in its international expansion, driven by official regulatory approvals in both the United Arab Emirates (UAE) and Turkey, alongside the first commercial sales for CellTolerance® in the region. These authorizations enable the full-scale launch of the CellTolerance® program in a region characterized by a record prevalence of disorders of the gut-brain interaction or DGBI.
The Middle East stands as a significant commercial growth driver for Mauna Kea Technologies, given the region’s exceptionally high rates of Irritable Bowel Syndrome (IBS) and food intolerances. A 2024 systematic review highlights an average IBS prevalence of 27% across the Arab world, with young adults in the UAE reporting symptoms in up to 39% of the population.
Click here to join our WhatsApp channel here
The Emirates Drug Establishment (EDE) and the Turkish Medicines and Medical Devices Agency (TITCK) granted official market authorization for the Cellvizio Gen 3 system and its specialized suite of probes. Following these approvals, Mauna Kea Technologies secured its first commercial sale of Cellvizio in the UAE dedicated to the CellTolerance® program.
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies commented: “The international expansion of Cellvizio and the CellTolerance test for food intolerances is gaining momentum, following our successful entries into Switzerland and the United Kingdom in the first quarter. The UAE and Turkey are highly promising markets for CellTolerance, where personalized medicine is a major priority and IBS and suspected food intolerance represents a critical public health challenge with some of the highest prevalence rates in the world.”
